制藥巨頭強(qiáng)生公司下屬的Janssen同比利時魯汶大學(xué)合作研究登革熱感染機(jī)制。這項研究得到了英國的Wellcome Trust基金會的支持。研究人員希望尋找到能夠?qū)顾兴姆N蚊蟲傳染的登革熱病原體的藥物。Janssen在傳染病領(lǐng)域有著豐富經(jīng)驗,曾開發(fā)出關(guān)于HIV、肝炎等疾病的抗病毒藥物。此次,Janssen希望在登革熱領(lǐng)域再次取得突破。
全球每年有3億9千萬人感染登革熱。這種疾病被認(rèn)為是最難以開發(fā)出相應(yīng)特效藥物的疾病之一。賽諾菲就曾經(jīng)在泰國研發(fā)過相應(yīng)的疫苗,但是研究最終宣告失敗。(生物谷Bioon.com)
詳細(xì)英文報道:
Via an academic alliance, drug giant Johnson & Johnson ($JNJ) aims to advance antiviral compounds against the rising threat of dengue infection. The company's Janssen unit has teamed up with Belgian academics, whose backing from the Wellcome Trust has aided the discovery of potential drugs against all four strains of the mosquito-borne illness.
Janssen, which has developed antivirals for HIV, hepatitis and other infections, has paid an upfront fee and agreed to pay future milestones and royalties to gain global rights to the compounds from a three-year alliance between the Rega Institute and the Centre for Drug Design and Discovery (CD3) at KU Leuven. The compounds, which are intended to stymie replication of the dengue virus, have shown effectiveness in animal tests. And the J&J deal fuels ongoing work to advance the preclinical program to human clinical trials.
Dengue infection, which afflicts an estimated 390 million people annually, has proven a difficult target for drug hunters. Sanofi ($SNY) reported mixed results from a midstage trial of a dengue vaccine in Thailand, yet the French drug giant has kept hope alive for the experimental vaccine with ongoing development and investment in manufacturing, Reuters noted. Also called "breakbone fever," dengue can cause severe fevers, pain and rashes and is sometimes fatal.
With no approved vaccines or drugs against dengue, J&J has seized rights to potentially pioneering drugs in the deal with KU Leuven. Of course, the collaborators face the gauntlet of clinical development for the unproven compounds in a dengue-infected population that has proven difficult to treat.
"It was a great experience to work with CD3 and the Wellcome Trust to discover this new class of dengue antivirals, which can be further developed by Janssen as the first potential medication to prevent and treat infections with the dengue virus," professor Johan Neyts of the Rega Institute, KU Leuven, said in a statement
四川省醫(yī)藥保化品質(zhì)量管理協(xié)會組織召開
2025版《中國藥典》將于2025年10月..關(guān)于舉辦四川省藥品生產(chǎn)企業(yè)擬新任質(zhì)量
各相關(guān)企業(yè): 新修訂的《中華人..四川省醫(yī)藥保化品質(zhì)量管理協(xié)會召開第七
四川省醫(yī)藥保化品質(zhì)量管理協(xié)會第七..“兩新聯(lián)萬家,黨建助振興”甘孜行活動
為深入貫徹落實省委兩新工委、省市..學(xué)習(xí)傳達(dá)中央八項規(guī)定精神專題會議
2025年4月22日,協(xié)會黨支部組織召..關(guān)于收取2025年度會費(fèi)的通知
各會員單位: 在過去的一年里,..四川省應(yīng)對新型冠狀病毒肺炎疫情應(yīng)急指
四川省應(yīng)對新型冠狀病毒肺炎疫情應(yīng)..四川省應(yīng)對新型冠狀病毒肺炎疫情應(yīng)急指
四川省應(yīng)對新型冠狀病毒肺炎疫情應(yīng)..